Aberrant VEGFR-2 and c-Met signaling facilitate tumour growth, angiogenesis and metastasis of cancer cells, which are linked to aggressive tumour behaviour, poor clinical prognosis and resistance to therapy [3,6,7]. The gene discussed is MET; the disease is cancer.